Key takeaway: Poly Medicure Limited submitted an investor presentation detailing its unaudited financial results for the first quarter ended June 30, 2026. The presentation highlighted a consolidated revenue growth of 30.3% year-over-year, with domestic revenue increasing by 16.2% and international revenue by 36.7%. The company reported a standalone operating EBITDA margin of 28.0%, exceeding its guidance range. Key updates included the launch of six new products and a significant increase in cash reserves to INR 854.7 crore. The presentation also noted a focus on sustainability, achieving a sixfold increase in solar power generation and an 18% reduction in scope 2 emissions. Management emphasized the importance of expanding their product portfolio and market presence, particularly in the cardiology and orthopedics segments, following recent acquisitions. The document concluded with a summary of the company's governance and leadership team.

Key takeaway: Poly Medicure Limited held its Q4 FY '26 earnings conference call on May 25, 2026, where management discussed the company's strategic transition towards high-technology medical devices. Managing Director Himanshu Baid highlighted investments in R&D and clinical teams, aiming for global recognition in high-end medical devices over the next five years. The company reported a standalone revenue of INR 1,662 crores for FY '26, a 4% increase year-on-year, with a gross margin of 68.1%. The consolidated revenue grew by 12.3% to INR 1,875 crores. Management guided for FY '27 standalone revenue between INR 1,900 crores to INR 1,950 crores and consolidated revenue of INR 2,300 crores to INR 2,400 crores. The company also announced the acquisition of Medyneo in Brazil to enhance its market presence. Despite challenges from raw material costs and logistics, management expressed confidence in maintaining growth and improving margins through strategic initiatives.

Key takeaway: Poly Medicure Limited submitted a revised investor presentation detailing its audited financial results for the fourth quarter and financial year ending March 31, 2026. The presentation highlighted a revenue increase to Rs. 1,875.3 crore for FY26, representing a 12.3% year-over-year growth. The company reported a gross profit margin of 68.2% for the consolidated results, with a standalone EBITDA margin of 26.8%, near the upper end of the guidance range. Management noted that the growth was supported by acquisitions and a strong product mix, with 35 new products launched during the year. The presentation also emphasized the company's commitment to sustainability, achieving an 8% reduction in Scope 2 emissions. Additionally, Poly Medicure's cash and cash equivalents stood at Rs. 842.2 crore as of March 31, 2026, indicating adequate liquidity.

Key takeaway: Poly Medicure Limited submitted an investor presentation detailing its audited financial results for the fourth quarter and financial year ended March 31, 2026. The presentation highlighted a standalone revenue of Rs. 443.0 crore for Q4 FY26, reflecting a 5.2% increase year-over-year. The company reported a gross profit margin of 66.6% and an operating EBITDA margin of 27.3%. Consolidated revenue for FY26 was Rs. 1,875.3 crore, with a growth of 12.3%. The document noted that the company achieved its highest-ever standalone quarterly revenue in Q4 FY26 and launched 35 new products during the fiscal year. Management emphasized the importance of acquisitions, such as PendraCare and Citieffe, in driving future growth. The presentation also discussed the company's commitment to sustainability, with a reported 8% reduction in Scope 2 emissions. Overall, the document provided a comprehensive overview of financial performance and strategic initiatives.

Key takeaway: Poly Medicure Limited submitted an updated investor presentation to the BSE and NSE on March 7, 2026. The presentation highlighted the company's extensive manufacturing capabilities, with 15 plants across five countries and a significant annual production capacity of over 1.8 billion medical devices. Management reported a strong focus on research and development, with over 390 patents and a pipeline of more than 100 products. The company emphasized its leadership in various medical device segments, including infusion therapy and renal care, and outlined strategic acquisitions to enhance its portfolio. Financial performance for the first nine months of FY 2026 showed a consolidated revenue increase of 9.1% year-over-year, with notable growth in both domestic and international markets. The presentation also detailed plans for expanding product offerings and increasing market presence in key regions.

Key takeaway: Poly Medicure Limited submitted an investor presentation detailing its unaudited financial results for the third quarter and nine months ended December 31, 2025. The presentation reported a consolidated revenue growth of 16.4% for Q3 FY26 compared to Q3 FY25, with domestic revenue growth at 16.2%. The operating EBITDA margin for Q3 FY26 was 24.2%, while the standalone EBITDA margin was 26.8%. The company launched 19 products in the first nine months of FY26 and reported adequate liquidity of Rs 839.8 crore. Key updates included ongoing clinical studies and regulatory approvals for new products. The presentation also discussed the positive impacts of recent trade deals and budget allocations on the medtech sector, suggesting a favorable environment for growth. The company highlighted its strong patent portfolio and recognition in the industry.